The concept on the use of glucocorticosteroids in the therapy of severe leptospirosis


DOI: https://dx.doi.org/10.18565/epidem.2020.10.1.60-6

Moysova D.L., Gorodin V.N.

Kuban State Medical University, Ministry of Health of Russia, Krasnodar, Russia
Objective. To create a concept on the use of glucocorticosteroids (GCS) in severe leptospirosis: to compare the efficiency of different GCS therapy regimens and to determine their safety, as well as to assess whether it is appropriate to use GCS in severe leptospirosis as a whole.
Subjects and methods. GCSs were used in the therapy of 231 patients with severe leptospirosis: Group 1 included 45 patients who received GCS pulse therapy; Group 2 consisted of 186 patients who had a medium-dose GCS regimen. A comparison group comprised 53 patients who did not take GCSs. The investigators determined the severity of multiple organ dysfunction (MOD) on the sequential organ failure assessment (SOFA) scale; as well as platelet counts in peripheral blood, fibrinogen level, activated partial thromboplastin time, prothrombin index, platelet aggregation area, von Willebrand factor ristomycin cofactor activity, minimum amplitude and lifetime for the presence of a clot, as evidenced by an electrocoagulogram, the levels of soluble fibrin-monomer complexes, plasma free hemoglobin, and the activity of glucose-6-phosphate dehydrogenase. Survival analysis was carried out using the Kaplan-Meier method with the Cox proportional hazards model. The risk ratio (RR [CI]) and odds ratio (OR [CI]) were calculated at a 95% confidence interval.
Results. In patients with leptospirosis and a SOFA MOD of > 16 scores, GCSs contribute to a reduction in the severity of MOD and can be used in the medium-dose GCS regimen or as pulse therapy. There is no evidence for the benefits of the impact of any GCS therapy regimen on patient survival. The indication for GCS therapy for severe leptospirosis is not only septic shock with adrenal insufficiency, but also other organ dysfunction. The use of GCS pulse doses should be strictly limited when there is a set of the following factors: consumption coagulopathy, Stage III acute kidney injury damage according to the Acute Kidney Injury Network (AKIN), and renal replacement therapy.
Conclusion. The proposed concept on the use of GCS will be able to optimize therapy for severe leptospirosis.

Literature



  1. Лебедев В.В., Авдеева М.Г., Шубич М.Г. Иктеро­геморрагический лептоспироз. Краснодар: Советская Кубань, 2001. 208 с.

    Lebedev V.V., Avdeeva M.G., Shubich M.G. [Icterohemorrhagic leptospirosis]. Krasnodar: Sovetskaya Kuban, 2001. 208 p. (In Russ.).



  2. Ayral F., Djelouadji Z., Raton V., Zilber A.L., Gasqui P., Faure E. et al. Hedgehogs and Mustelid Species: Major Carriers of Pathogenic Leptospira, a Survey in 28 Animal Species in France. PLoSOne 2016; 11(9): e0162549. DOI: 10.1371

  3. Cleto S.A., Rodrigues С.Е., Malaque С.М., Sztajnbok J., Seguro А.С., L. Andrade. Hemodiafiltration Decreases Serum Levels of Inflammatory Mediators in Severe Leptospirosis: A Prospective Study. PLoSOne 2016; 11(8): e0160010. DOI: 10.1371/journal.pone.0160010

  4. Singer M., Deuschman C. S., Seymour C. W. et al. The Third International Consensus definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315(8): 801–10. DOI:10.1001/jama.2016.0287

  5. Ludwig B., Zotzmann V., Bode C., Staudacher D.L., Zschiedrich S. Lethal pulmonary hemorrhage syndrome due to Leptospira infection transmitted by pet rat. IDCases 2017; (8): 84–6.

  6. Delmas B., Jabot J., Chanareille P, Ferdynus C., Allyn J., Allou N. et al. Leptospirosis in ICU: A Retrospective Study of 134 Consecutive Admissions. Crit. Care Med. 2018; 46(1): 93–9. DOI: 10.1097/CCM. 0000000000002825.

  7. Shenoy V.V., Nagar V.S., Chowdhury A.A., Bhalgat P.S., Juvale N.I. Pulmonary leptospirosis: An excellent response to bolus methylprednisolone. Postgrad. Med. J. 2006; 82(971): 602–6.

  8. Minor K., Mohan A. Severe leptospirosis: treatment with intravenous corticosteroids and supportive care. Am. J. Emerg. Med. 2013; 31(2): 449. e1–2. DOI: https://doi.org/10.1016/j.ajem.2012.06.016

  9. Cerdas-Quesada С. Potential benefits of plasma exchange by apheresis on the treatment of severe Icteric Leptospirosis: Case report and literature review. Transfus. Apher. Sci. 2011; 45(2): 191–4. DOI: 10.1016/j.transci. 2011.07.012

  10. Мойсова Д.Л., Усатиков С.В., Шкиря Т.В., Городин В.Н. Оценка информативности лабораторных тестов для диагностики варианта коагулопатии при лептоспирозе. Инфекционные болезни 2018; 16(4): 22–33. DOI: 10.20953/1729-9225-2018-4-22-33

    Moisova D.L., Usatikov S.V., Shkira T.V., Gorodin V.N. [Assessment of information value of laboratory tests for diagnosis of coagulopathy variant in case of leptospirosis]. Infekcionnye bolezni 2018; 16(4): 22–33. (In Russ.). DOI: 10.20953/1729-9225-2018-4-22-33



  11. Городин В.Н., Мойсова Д.Л., Бахтина В.А., Зотов С.В. Тренды современного лептоспироза. Эпидемиол. и инфекц. бол. 2018; 23(2): 93–100. DOI: 10.18821/1560-9529-2018-23-2-93-100

    Gorodin V.N., Moisova D.L., Bakhtina V.A., Zotov S.V. [Trends of modern leptospirosis]. Epidemiologiya i infekcionnye bolezni 2018; 23(2): 93–100. (In Russ.). DOI: 10.18821/1560-9529-2018-23-2-93-100



  12. Синьков С.В., Шапошников С.А., Величко Д.С., Заболотских И.Б. Характеристика гемостаза с позиции энергодефицитных состояний. Кубанский медицинский научный вестник 2012; 3(132): 143–8.

    Sinkov S.V., Shaposhnikov S.A., Velichko D.S., Kolovotsky I.B. [Characteristic of hemostasis from the position of energy deficiency states]. Kubanskij nauchnyi meditsinskii vestnik 2012; 3(132): 143–8. (In Russ.).



  13. Annane D. Corticosteroids for severe sepsis: an evidence-based guide for physicians. Ann Intensive Care 2011; 1(1): 7. DOI: 10.1186/2110-5820-1-7.

  14. Мarik P., Pastores S., Annane D. et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit. Care Med. 2008; 36(6): 1937–49. DOI:10.1097/CCM.0b013e31817603ba

  15. Steinberg K.P., Hudson L.D., Goodman R.B. et al. The National Heart, Lung and Blood Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N. Engl. J. Med. 2006; 354: 1671–84. 10.1007/BF03026873.pdf

  16. Meduri U., Golden E., Freire A. et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007; 131: 954–63.

  17. Torres A., Sibila O., Ferrer M., Polverino E., Menendez R., Mensa J. et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high in ammatory response: a randomized clinical trial. JAMA 2015; 313(7): 677–86.


About the Autors


Diana L. Moysova, Cand. Med. Sci., Associate Professor, Department of Infectious Diseases and Epidemiology, Kuban State Medical University, Ministry of Health of Russia, Krasnodar, Russia; e-mail: moisova.di@yandex.ru; ORCID: https://orcid.org/000-0003-3920-5997
Prof. Vladimir N. Gorodin, MD, Head, Department of Infectious Diseases and Epidemiology, Kuban State Medical University, Ministry of Health of Russia, Krasnodar, Russia; e-mail: vgorodin@mail.ru; ORCID: https://orcid.org/0000-0003-3062-7595


Similar Articles


Бионика Медиа